Comparison of Blood Lead Levels in Patients With Alzheimer's Disease and Healthy People.

IF 2.7 4区医学 Q2 CLINICAL NEUROLOGY

American Journal of Alzheimers Disease and Other Dementias Pub Date : 2018-12-01 Epub Date: 2018-08-22 DOI:10.1177/1533317518794032

Babak Fathabadi, Mohammad Dehghanifiroozabadi, Jan Aaseth, Gholamreza Sharifzadeh, Samaneh Nakhaee, Ali Rajabpour-Sanati, Alireza Amirabadizadeh, Omid Mehrpour

{"title":"Comparison of Blood Lead Levels in Patients With Alzheimer's Disease and Healthy People.","authors":"Babak Fathabadi, Mohammad Dehghanifiroozabadi, Jan Aaseth, Gholamreza Sharifzadeh, Samaneh Nakhaee, Ali Rajabpour-Sanati, Alireza Amirabadizadeh, Omid Mehrpour","doi":"10.1177/1533317518794032","DOIUrl":null,"url":null,"abstract":"Background: It is argued that breakdown of β-amyloid in the brain causes deposition of senescent plaques and therefore Alzheimer's disease (AD). One of the influential factors for increasing level of this protein is exposure to lead. Our aim was to compare blood lead levels (BLLs) between patients with AD and healthy controls.Methods: This case-control study was performed on all patients with cognitive impairment who were referred to the Neurological Clinic of Birjand in 2016 to 2017. Patients were referred to the laboratory for measurement of their serum levels of lead. The controls and patients were matched by age and sex.Results: In the AD case group, the average BLL was 22.22 ± 28.57 μg/dL. Mann-Whitney U test showed that BLLs were significantly higher in the patients than in the controls. The unadjusted odds ratio for BLL among the patients was 1.05 (95% confidence interval: 1.01-1.09; P = .01) compared to the controls.Conclusion: In the present study, BLL was associated with AD.","PeriodicalId":50816,"journal":{"name":"American Journal of Alzheimers Disease and Other Dementias","volume":"33 8","pages":"541-547"},"PeriodicalIF":2.7000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10852476/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Alzheimers Disease and Other Dementias","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1533317518794032","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/8/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: It is argued that breakdown of β-amyloid in the brain causes deposition of senescent plaques and therefore Alzheimer's disease (AD). One of the influential factors for increasing level of this protein is exposure to lead. Our aim was to compare blood lead levels (BLLs) between patients with AD and healthy controls.

Methods: This case-control study was performed on all patients with cognitive impairment who were referred to the Neurological Clinic of Birjand in 2016 to 2017. Patients were referred to the laboratory for measurement of their serum levels of lead. The controls and patients were matched by age and sex.

Results: In the AD case group, the average BLL was 22.22 ± 28.57 μg/dL. Mann-Whitney U test showed that BLLs were significantly higher in the patients than in the controls. The unadjusted odds ratio for BLL among the patients was 1.05 (95% confidence interval: 1.01-1.09; P = .01) compared to the controls.

Conclusion: In the present study, BLL was associated with AD.

查看原文本刊更多论文

阿尔茨海默病患者与健康人血液中铅含量的比较。

背景：有观点认为，β-淀粉样蛋白在大脑中的分解会导致衰老斑块沉积，从而引发阿尔茨海默病（AD）。铅暴露是导致这种蛋白质水平升高的影响因素之一。我们的目的是比较阿兹海默症患者和健康对照组的血铅水平（BLLs）：这项病例对照研究的对象是 2016 年至 2017 年转诊至比尔詹德神经诊所的所有认知障碍患者。患者被转诊至实验室测量血清中的铅含量。对照组和患者的年龄和性别匹配：在 AD 病例组中，平均 BLL 为 22.22 ± 28.57 μg/dL。Mann-Whitney U 检验显示，患者的 BLL 明显高于对照组。与对照组相比，患者 BLL 的未调整几率比为 1.05（95% 置信区间：1.01-1.09；P = .01）：在本研究中，BLL 与注意力缺失症有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Alzheimers Disease and Other Dementias GERIATRICS & GERONTOLOGY-CLINICAL NEUROLOGY

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： American Journal of Alzheimer''s Disease and other Dementias® (AJADD) is for professionals on the frontlines of Alzheimer''s care, dementia, and clinical depression--especially physicians, nurses, psychiatrists, administrators, and other healthcare specialists who manage patients with dementias and their families. This journal is a member of the Committee on Publication Ethics (COPE).